Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Skip ContextLogic as Its Revenue Continues to Decline

By Alex Sirois, InvestorPlace Contributor
WISH stock was supposed to be a great e-commerce disruptor, but its weak business model is leading to decreasing revenues.

7 F-Rated Stocks to Sell Before We Reach Christmas

By Louis Navellier and the InvestorPlace Research Staff
It's just as important to know what stocks to sell as it is to know what stocks to buy. These stocks are prime examples of stocks to drop now.

Upstart Stock Has a Valuation Issue That Eclipses Any Upside Thesis

By David Moadel, InvestorPlace Contributor
UPST stock seems to have gotten ahead of itself, but patient investors can wait as the AI-powered fintech company definitely has potential.

Carnival Corporation Stock May Be Turning Around, But Value Investors Should Stay Away

By Muslim Farooque, InvestorPlace Contributor
CCL stock is likely to be weighed down by Carnival's substantial debt load and unimpressive sales

Google Is Never Going to Buy BlackBerry

By Will Ashworth, InvestorPlace Contributor
BlackBerry continues losing money. Yet BB stock is up almost 66% in 2021. Is there something I’m missing about its business? I don’t think so. 

Cassava Is a Sell After Accusations of Data Manipulation

By Larry Ramer, InvestorPlace Contributor
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock.

Affirm Stock May Have a Bright Future, But It Is Already Priced In

By Larry Ramer, InvestorPlace Contributor
Facing very tough competition and losing a great deal of money, Affirm is not an appealing name. Investors should sell AFRM stock.

Ocugen Stock Looks Poised to Take a Tumble Right Here

By Larry Ramer, InvestorPlace Contributor
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock.

Lucid Stock Has a Frightening Valuation on Only a Little Good News

By GS Early
EVs are starting to ramp up now from both the upstarts and the big automakers. It's an exciting time, and LCID stock offers its own thrills.

Microvision Is Almost Indefensible After This Awful Earnings Surprise

By David Moadel, InvestorPlace Contributor
MVIS stock plunged after the company revealed some dreadful fiscal stats - and just because the stock is lower, doesn't mean that it's a buy.

With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News’

By Thomas Niel, InvestorPlace Contributor
With its chances of experiencing another sharp slide in price likely. If you own OCGN stock today, cash out ASAP to avoid holding the bag. If you don't own it? Avoid at all costs.

Massive Jump Is a Great Selling Opportunity For Novavax Stock

By Josh Enomoto, InvestorPlace Contributor
Although NVAX stock has recently been bolstered by good news, it may not be enough to overcome vaccine disinformation.

UBER Stock Doesn’t Look as If It Will Rebound Anytime Soon

By Joel Baglole, InvestorPlace Contributor
The only question left regarding shares of Uber Technologies is: where's the bottom? At $43.11 per share, the San Francisco-based ride hailing and food delivery company's stock is now down 33% from its 52-week high of $64.05. Uber stock has fallen 21% in the past six months, including a 6% decline in the last month.

Don’t Fall for Peloton Stock’s Latest Rally

By Louis Navellier and the InvestorPlace Research Staff
PTON stock has begun to rally again, but it probably won't get far as controversies and supply chain problems weigh it down.

Moderna’s Outlook Is Directly Tied to the Eventual Receding of Covid-19

By Muslim Farooque, InvestorPlace Contributor
With Covid-19 receding and a one-dimensional product pipeline, MRNA stock is a one-trick-pony without any long-term prospects.

Ocugen Neared $16 Yesterday, But I’ll Eat 4 Hats If It Gets to $32

By Will Ashworth, InvestorPlace Contributor
OCGN stock has moved higher despite little evidence anything’s changed regarding Ocugen’s revenue potential in the U.S.

SPCE Could Fall Even Further Than Ground Level

By Mark R. Hake, CFA
Virgin Galactic stock could fall further even though it's at a trough. SPCE stock is not worth investing in just yet until it's clear whether its cash will cover the ongoing cash burn.

Many Factors Could Still Sink Palantir Stock

By Thomas Niel, InvestorPlace Contributor
As Palantir's risk continues to vastly exceed its near-term potential gains, steering clear of PLTR stock remains your best move.

With its Current Prognosis, Avoid Teladoc Stock

By Louis Navellier and the InvestorPlace Research Staff
With its current prognosis calling for another drop in price, steer clear of TDOC stock.
Load More Articles